pentadecapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-18. Numbers and descriptions here follow the published literature rather than marketing material.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
== Structure == The catalytic peptide of ALS in Arabidopsis thaliana (mouse-eared cress) is a chloroplastic protein consisting of 670 residues, the last 615 of which form the active form. Three main domains are found, with two thiamine pyrophosphate sandwiching a DHS-like NAD/FAD-binding domain. In SCOP assignment, these subunits are named d1yhya1, d1yhya2, and d1yhya3 from the N-terminal to the C-terminal. The structure of acetolactate synthase that was used for the picture on this page was determined using X-ray diffraction at 2.70 angstroms. There are five specific ligands that interact with this protein. The five are listed below.
=== Schools === Le Havre is located in the Academy of Rouen. The city operates 55 kindergartens (254 classes) and 49 communal primary schools (402 classes). The department manages 16 colleges and the region of Normandy manages 9 schools. The Jules Valles college in Caucriauville is classified as a sensitive institution and eleven colleges are in a priority education zone (ZEP). A boarding school of excellence, the Claude Bernard college, opened in 2011. The first college in Le Havre dates to the 16th century, the high school François I was founded during the Second Empire and is the oldest in Le Havre. The philosopher Jean-Paul Sartre (1905–1980) and Raymond Aron (1905–1983) taught there. The writer Armand Salacrou (1899–1989) studied in this institution.
The bacterial one-hybrid (B1H) system is a method for identifying the sequence-specific target site of a DNA-binding domain. In this system, a given transcription factor (TF) is expressed as a fusion to a subunit of RNA polymerase. In parallel, a library of randomized oligonucleotides representing potential TF target sequences are cloned into a separate vector containing the selectable genes HIS3 and URA3. If the DNA-binding domain (bait) binds a potential DNA target site (prey) in vivo, it will recruit RNA polymerase to the promoter and activate transcription of the reporter genes in that clone. The two reporter genes, HIS3 and URA3, allow for positive and negative selections, respectively. At the end of the process, positive clones are sequenced and examined with motif-finding tools in order to resolve the favoured DNA target sequence.
Sources: en.wikipedia.org
== Structure and reactivity == The structure of α-PMTX consists of 13 amino acid residues with the sequence Arg-Ile-Lys-Ile-Gly-Leu-Phe-Asp-Gln-Leu-Ser-Lys-Leu-NH2. Replacement of the lysine residue at position 12 of α-PMTX with arginine results in β-PMTX. This single amino acid difference appears to be responsible for a difference in potency, as β-PMTX appeared to be five times as potent as α-PMTX in lobster neuromuscular junctions. The location of the three basic residues at positions 1, 3 and 12 was found to be crucial for toxin action. The length of the compound also appeared to be crucial for its function. Analogues of α- and β-PMTX have been synthesized by implementing changes in the amino acid sequence to understand the structure-activity relationship (SAR) with respect to activity for human voltage-gated sodium channel 1.1 (hNaV1.1) and selectivity over other isoforms of human Na+ channels such as hNaV1.2-1.7. 3D models have suggested that β-PMTX may adopt a kinked conformation assisted by its Gly-5 residue and is further stabilised by electrostatic interaction between its negatively charged Asp-8 and positively charged residues Arg-1 and/or Lys-3. This led to the hypothesis that a β-turn-like conformation depending on Gly-5, since it is the most sterically flexible amino acid, could be an important feature of the pharmacologically active conformation. This was tested by replacing Gly-5 with other (β-)turn-favouring residues, but this change was not tolerated.
=== Respiratory effects === The most severe side effect associated with buprenorphine is respiratory depression (insufficient breathing). It occurs more often in those who are also taking benzodiazepines or alcohol, or have underlying lung disease. The usual reversal agents for opioids, such as naloxone, may be only partially effective, and additional efforts to support breathing may be required. Respiratory depression may be less than with other opioids, particularly with chronic use. In the setting of acute pain management, though, buprenorphine appears to cause the same rate of respiratory depression as other opioids such as morphine. Central sleep apnea is possible with long-term use, possibly resolving with dose reduction.
Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is administered by subcutaneous injection (injection under the skin). It works by inactivating tumor necrosis factor (TNF). Common side effects include upper respiratory tract infections, pain at the site of injection, rash, and headache. Other side effects may include serious infections, cancer, anaphylaxis, reactivation of hepatitis B, new onset or exacerbation of demyelinating diseases (such as multiple sclerosis), heart failure, liver failure, and aplastic anemia. Use during pregnancy is not recommended, but some sources show use during breastfeeding may be safe. Adalimumab was approved for medical use in the United States in 2002. It is on the World Health Organization's List of Essential Medicines. It is available as a biosimilar medication. In 2023, it was the 244th most commonly prescribed medication in the United States, with more than 3 million prescriptions.
Sources: en.wikipedia.org
negative supercoiling The supercoiling of a double-stranded DNA molecule in the direction opposite to the turn of the double helix itself (e.g. a left-handed coiling of a helix with a right-handed turn). Contrast positive supercoiling.
But Edith said she had agreed to marry Field only because she felt "on the shelf" and had begun to doubt that Tolkien still cared for her. She explained that, because of Tolkien's letter, everything had changed. On 8 January 1913 Tolkien travelled by train to Cheltenham and was met on the platform by Edith. The two took a walk into the countryside, sat under a railway viaduct, and talked. By the end of the day, Edith had agreed to accept Tolkien's proposal. She wrote to Field and returned her engagement ring. Field was "dreadfully upset at first", and the Field family was "insulted and angry". Upon learning of Edith's new plans, Jessop wrote to her guardian, "I have nothing to say against Tolkien, he is a cultured gentleman, but his prospects are poor in the extreme, and when he will be in a position to marry I cannot imagine. Had he adopted a profession it would have been different." Following their engagement, Edith reluctantly announced that she was converting to Catholicism at Tolkien's insistence. Jessop, "like many others of his age and class ... strongly anti-Catholic", was infuriated, and he ordered Edith to find other lodgings. Edith Bratt and Ronald Tolkien were formally engaged at Birmingham in January 1913, and married at St Mary Immaculate Catholic Church at Warwick, on 22 March 1916. In a 1941 letter to Michael, Tolkien expressed admiration for his wife's willingness to marry a man with no job, little money, and no prospects except the likelihood of being killed in the Great War.
== Enzymes == Glycogen phosphorylase with Pyridoxal phosphate as prosthetic group Alpha-1,4 → alpha-1,4 glucan transferase Alpha-1,6-glucosidase Phosphoglucomutase Glucose-6-phosphatase (absent in muscles)
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.